| Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors |
19 |
| Fatal intoxication by 5F-ADB and diphenidine: Detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q-TOFMS |
17 |
| Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in legal high' products and human urine samples |
14 |
| Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs |
13 |
| Analysis of new psychoactive substances in oral fluids by means of microextraction by packed sorbent followed by ultra-high-performance liquid chromatography-tandem mass spectrometry |
13 |
| Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine |
12 |
| The emergence of new psychoactive substance (NPS) benzodiazepines: A review |
12 |
| Potency of Delta(9)-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology |
12 |
| Application of a screening method for fentanyl and its analogues using UHPLC-QTOF-MS with data-independent acquisition (DIA) in MSE mode and retrospective analysis of authentic forensic blood samples |
12 |
| Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA |
12 |
| Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry |
11 |
| Metabolic profiling of synthetic cannabinoid 5F-ADB by human liver microsome incubations and urine samples using high-resolution mass spectrometry |
11 |
| Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD) |
10 |
| Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) |
10 |
| Potential impact of the sewer system on the applicability of alcohol and tobacco biomarkers in wastewater-based epidemiology |
10 |
| UPLC-MS/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units |
10 |
| A review of chemical spot' tests: A presumptive illicit drug identification technique |
10 |
| Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users |
9 |
| Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in legal high products and human urine specimens |
9 |
| Human in vivo metabolism study of LGD-4033 |
9 |
| Development of a sensitive untargeted liquid chromatography-high resolution mass spectrometry screening devoted to hair analysis through a shared MS2 spectra database: A step toward early detection of new psychoactive substances |
9 |
| Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE |
9 |
| European guidelines for workplace drug testing in oral fluid |
8 |
| Detection of Delta(9) THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices |
8 |
| Comprehensive investigation on synthetic cannabinoids: Metabolic behavior and potency testing, using 5F-APP-PICA and AMB-FUBINACA as model compounds |
8 |
| Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers |
8 |
| A rapid non-target screening method for determining prohibited substances in human urine using liquid chromatography/high-resolution tandem mass spectrometry |
8 |
| Sensitivity of doping biomarkers after administration of a single dose testosterone gel |
7 |
| Investigating the appearance of new psychoactive substances in South Australia using wastewater and forensic data |
7 |
| Combined administration of microdoses of growth hormone and erythropoietin: Effects on performance and evaluation of GH detection capability using anti-doping methods |
7 |
| In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA |
7 |
| Prediction of designer drugs: Synthesis and spectroscopic analysis of synthetic cathinone analogs that may appear on the Swedish drug market |
7 |
| Stability of mephedrone and five of its phase I metabolites in human whole blood |
7 |
| The use of a valid and straightforward method for the identification of higenamine in dietary supplements in view of anti-doping rule violation cases |
6 |
| Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data |
6 |
| Detectability of fentanyl and designer fentanyls in urine by 3 commercial fentanyl immunoassays |
6 |
| Chemical profiling of the synthetic cannabinoid MDMB-CHMICA: Identification, assessment, and stability study of synthesis-related impurities in seized and synthesized samples |
6 |
| Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder |
6 |
| Detection of prohibited substances in equine hair by ultra-high performance liquid chromatography-triple quadrupole mass spectrometry - application to doping control samples |
6 |
| Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse |
6 |
| Keratinous matrices for the assessment of drugs of abuse consumption: A correlation study between hair and nails |
6 |
| Detection of erythropoiesis-stimulating agents in a single dried blood spot |
6 |
| Automated optimization of XCMS parameters for improved peak picking of liquid chromatography-mass spectrometry data using the coefficient of variation and parameter sweeping for untargeted metabolomics |
6 |
| Assessing serum albumin concentration following exercise-induced fluid shifts in the context of the athlete biological passport |
6 |
| Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine |
6 |
| Assessing the toxicological significance of new psychoactive substances in fatalities |
6 |
| Summary statistics for drug concentrations in post-mortem femoral blood representing all causes of death |
6 |
| Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism: Progress, outlook, and challenges |
6 |
| Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls |
6 |
| Erythropoietic effects of low-dose cobalt application |
6 |
